Latest Period
Q2 2026
Security Snapshot
Monopar Therapeutics - Common Stock, $0.001 par value (MNPR) Institutional Ownership
CUSIP: 61023L207
13F Institutional Holders and Ownership History from Q3 2024 to Q2 2026
Institutions Reporting
95
Shares (Excl. Options)
6,222,139
Price
$92.59
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, $0.001 par value
- Symbol
- MNPR on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 6,222,139
- Total 13F value
- $576,133,337
- Portfolio coverage rank
- 0%
- Share change
- -8,061
- Value change
- +$12,667,679
- Number of holders
- 95
- Shares outstanding
- 6,667,745
- SEC-reported price per share
- $114.66
- Insider filing price
- $114.66
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- MNPR - Monopar Therapeutics - Common Stock, $0.001 par value is tracked under CUSIP 61023L207.
- 95 institutions reported positions in Q2 2026.
- 6 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 82 to 95 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $341,548,688 to $576,133,337.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 95 institutions filings for Q2 2026.
Security key
61023L207
Latest holder period
Q2 2026
13F holders
95
13D/G owners
6
CIK / CUSIP context first
Open Q2 2026 holders
MNPR full holder history
Monopar Therapeutics SEC filings
Monopar Therapeutics company facts
Monopar Therapeutics insider transactions
Monopar Therapeutics 13D/G history
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 61023L207:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
6
Security
MNPR
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| JANUS HENDERSON GROUP PLC | 20% | +1.6% | $105,138,701 | +$9,391,992 | 1,287,368 | +9.8% | JANUS HENDERSON GROUP PLC | 30 Sep 2025 |
| Monopar Therapeutics | 13% | $31,414,229 | 704,829 | Hendricks Diane | 09 Dec 2024 | |||
| RA CAPITAL MANAGEMENT, L.P. | 9.9% | 0% | $43,402,756 | -$4,890,637 | 667,632 | -10% | RA Capital Management, L.P. | 31 Dec 2025 |
| ASTRAZENECA PLC | 7.8% | $34,126,392 | 522,667 | AstraZeneca PLC | 31 Dec 2025 | |||
| Adage Capital Management, L.P. | 4.8% | -24% | $31,485,818 | -$9,712,000 | 324,195 | -24% | Adage Capital Management, L.P. | 30 Jun 2026 |
| Saturn V Capital Management LP | 4.7% | -10% | $30,435,854 | -$3,131,343 | 313,384 | -9.3% | Saturn V Capital Management LP | 30 Jun 2026 |
As of 30 Jun 2026, 95 institutional investors reported holding 6,222,139 shares of Monopar Therapeutics - Common Stock, $0.001 par value (MNPR). This represents 93% of the company’s total 6,667,745 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
85%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Jupiter Topco LLC | 20% | 1,312,129 | 0% | 0.05% | $121,699,965 |
| RA CAPITAL MANAGEMENT, L.P. | 10% | 667,207 | 0% | 0.54% | $61,776,696 |
| BlackRock, Inc. | 5.2% | 348,819 | +10% | 0% | $32,297,151 |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 4.9% | 323,745 | 0% | 0.31% | $29,975,550 |
| Saturn V Capital Management LP | 4.7% | 311,976 | -9.7% | 4.1% | $28,885,858 |
| Siren, L.L.C. | 4.1% | 270,118 | 0% | 0.51% | $25,010,226 |
| ADAR1 Capital Management, LLC | 3.3% | 217,595 | -18% | 0.95% | $20,147,121 |
| Polar Capital Holdings Plc | 3.2% | 214,469 | -5.3% | 0.06% | $19,857,685 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.1% | 209,711 | -4% | 0% | $19,417,141 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 3.1% | 209,195 | -32% | 0.03% | $19,369,365 |
| TCG Crossover Management, LLC | 3% | 203,327 | +54% | 0.45% | $18,826,047 |
| WELLINGTON MANAGEMENT GROUP LLP | 2.4% | 158,437 | -9.1% | 0% | $14,669,682 |
| ORBIMED ADVISORS LLC | 2.4% | 157,423 | 0.28% | $14,575,796 | |
| Candriam S.C.A. | 2.1% | 143,339 | 0.06% | $13,258,989 | |
| Balyasny Asset Management L.P. | 2% | 134,543 | -1.4% | 0.02% | $12,457,336 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.7% | 112,578 | +13% | 0% | $10,426,384 |
| Alyeska Investment Group, L.P. | 1.5% | 100,000 | 0% | 0.02% | $9,259,000 |
| STATE STREET CORP | 1.4% | 92,551 | +4.7% | 0% | $8,569,297 |
| Vivo Capital, LLC | 1.4% | 90,500 | 0% | 0.77% | $8,379,395 |
| Driehaus Capital Management LLC | 1.3% | 84,040 | +153% | 0.05% | $7,781,264 |
| Bank of New York Mellon Corp | 1.2% | 76,942 | -2.1% | 0% | $7,124,057 |
| Vestal Point Capital, LP | 1.1% | 75,727 | +16% | 0.16% | $7,011,563 |
| Longaeva Partners L.P. | 0.84% | 55,834 | 0.15% | $5,169,670 | |
| NEUBERGER BERMAN GROUP LLC | 0.83% | 55,194 | +30% | 0% | $5,110,413 |
| MILLENNIUM MANAGEMENT LLC | 0.75% | 50,311 | -5% | 0% | $4,658,295 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
8
Latest
Q2 2026
Rows shown
1-8 of 8
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 6,222,139 | $576,133,337 | +$12,667,679 | $92.59 | 95 |
| 2026 Q1 | 6,235,981 | $341,548,688 | +$37,301,460 | $54.79 | 82 |
| 2025 Q4 | 5,529,904 | $360,987,109 | +$75,159,494 | $65.30 | 74 |
| 2025 Q3 | 4,336,026 | $354,298,233 | +$99,764,618 | $81.67 | 55 |
| 2025 Q2 | 3,176,497 | $113,304,454 | +$10,313,028 | $35.78 | 43 |
| 2025 Q1 | 2,886,019 | $109,374,138 | +$11,536,779 | $36.41 | 34 |
| 2024 Q4 | 2,578,295 | $57,125,546 | +$56,777,792 | $22.00 | 18 |
| 2024 Q3 | 15,707 | $105,865 | +$105,865 | $6.74 | 6 |